2-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide | 450354-79-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide
• 英文别名: 2-methyl-N-phenethyl-5-(phenylsulfonyl)benzenesulfonamide；5-(benzenesulfonyl)-2-methyl-N-(2-phenylethyl)benzenesulfonamide
• CAS: 450354-79-7
• 化学式: C₂₁H₂₁NO₄S₂
• 分子量: 415.534
• InChiKey: LIZDBEGZOXTKPD-UHFFFAOYSA-N

物化性质

• 沸点：
  629.6±65.0 °C(Predicted)
• 密度：
  1.290±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide 、 丙酮 在 正丁基锂 、 水 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 1.33h， 以11%的产率得到2-(2-hydroxy-2-methylpropyl)-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide
  参考文献：
  名称：

  WO2006/124875

  摘要：

  公开号：
• 作为产物：
  描述：

  2-苯乙胺 、 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以82%的产率得到2-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide
  参考文献：
  名称：

  Identification of Diarylsulfone Sulfonamides as Secreted Frizzled Related Protein-1 (sFRP-1) Inhibitors

  摘要：

  Inhibitor of secreted frizzled related protein-1 (sFRP-1) would be a novel potential osteogenic agent, since loss of sFRP-1 affects osteoblast proliferation, differentiation, and activity, resulting in improved bone mineral density, quality, and strength. We have identified small molecule diarylsulfone sulfonamide derivatives as sFRP-1 inhibitors. Struture-activity relationship generated for various regions of the scaffold was utilized to improve the biochemical profile, resulting in the identification of potent selective analogues, such as 16 with desirable pharmaceutical profile.

  DOI：

  10.1021/jm801069w

文献信息

• Diarylsulfone sulfonamides and use thereof
  申请人：Gopalsamy Ariamala

  公开号：US20060276464A1

  公开（公告）日：2006-12-07

  Compounds of Formula 1, or pharmaceutically acceptable salts thereof, are provided: which are modulators of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety of disorders, including osteoporosis.

  提供公式1的化合物或其药用可接受盐：它们是分泌的毛细胞突变相关蛋白-1的调节剂。这些化合物和含有这些化合物的组合物可用于治疗多种疾病，包括骨质疏松症。
• DIARYLSULFONE SULFONAMIDES AND USE THEROF
  申请人：Wyeth

  公开号：EP1879859A2

  公开（公告）日：2008-01-23
• [EN] DIARYLSULFONE SULFONAMIDES AND USE THEROF<br/>[FR] SULFAMIDES DE DIARYLSULFONE ET LEUR UTILISATION
  申请人：WYETH CORP

  公开号：WO2006124875A2

  公开（公告）日：2006-11-23

  [EN] Compounds of Formula (I), or pharmaceutically acceptable salts thereof, are provided, which are modulators of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety of disorders, including osteoporosis.
  [FR] L'invention porte sur des composés de formule (I), ou sur leurs sels acceptables d'un point de vue pharmaceutique, qui sont des modulateurs de la protéine Frizzled sécrétée 1. Les composés et les compositions contenant ces composés peuvent être utilisés pour traiter diverses pathologiques telles que l'ostéoporose.
• WO2006/124875
  申请人：——

  公开号：——

  公开（公告）日：——
• Identification of Diarylsulfone Sulfonamides as Secreted Frizzled Related Protein-1 (sFRP-1) Inhibitors
  作者：Ariamala Gopalsamy、Mengxiao Shi、Barbara Stauffer、Ramesh Bahat、Julia Billiard、Helga Ponce-de-Leon、Laura Seestaller-Wehr、Shoichi Fukayama、Annamarie Mangine、Robert Moran、Girija Krishnamurthy、Peter Bodine

  DOI：10.1021/jm801069w

  日期：2008.12.25

  Inhibitor of secreted frizzled related protein-1 (sFRP-1) would be a novel potential osteogenic agent, since loss of sFRP-1 affects osteoblast proliferation, differentiation, and activity, resulting in improved bone mineral density, quality, and strength. We have identified small molecule diarylsulfone sulfonamide derivatives as sFRP-1 inhibitors. Struture-activity relationship generated for various regions of the scaffold was utilized to improve the biochemical profile, resulting in the identification of potent selective analogues, such as 16 with desirable pharmaceutical profile.